Literature DB >> 9262540

Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis.

A S Banker1, J F Arevalo, D Munguia, F M Rahhal, B Ishimoto, C Berry, E De Clercq, R Ochabski, I Taskintuna, W R Freeman.   

Abstract

PURPOSE: To evaluate the decrease in intraocular pressure associated with cidofovir (1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate; HPMPC) intravitreal injections.
METHODS: We followed up 97 eyes of 63 patients with acquired immunodeficiency syndrome (AIDS) who had cytomegalovirus retinitis and had been treated with up to nine 20-microgram intravitreal cidofovir injections. Measurements were taken at baseline, between 2 and 3 weeks, and at 5 to 6 weeks after injections. Anterior chamber fluorophotometry was studied in seven eyes (four patients) before and after injections. Ciliary body anatomy was evaluated in two patients.
RESULTS: After the first intravitreal injection, mean intraocular pressure was 2.2 mm Hg lower than that at baseline at 2 to 3 weeks (P < .001) and 1.3 mm Hg lower than at baseline at 5 to 6 weeks (P = .0025). After the second injection, mean pressure was 2.6 mm Hg lower at 2 to 3 weeks (P = .0013) and 1.5 mm Hg lower at 5 to 6 weeks (P = .043). After subsequent injections, however, the decrease was less than 1 mm Hg, suggesting that a plateau had been reached. Pressure in eyes with anterior uveitis after the first injection was lower than that in eyes without anterior uveitis (P < .0001). The mean rate of aqueous flow decreased from 2.8 to 1.9 microliters per minute 2 to 4 weeks after injection (P < .015). Ultrasound biomicroscopy disclosed that severe hypotony after cidofovir injections is associated with ciliary body atrophy.
CONCLUSIONS: Intraocular pressure decreases after the initial 20-microgram cidofovir intravitreal injection. However, eyes stabilize (pressure plateaus) after three injections. Effects on the ciliary body are the main cause of the decrease after cidofovir injections.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9262540     DOI: 10.1016/s0002-9394(14)70781-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis.

Authors:  J Ambati; K B Wynne; M C Angerame; M R Robinson
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

2.  Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir.

Authors:  Lingyun Cheng; Karl Y Hostetler; Jeffery Lee; Hyoung Jun Koh; James R Beadle; Kenichiro Bessho; Mitsuko Toyoguchi; Kathy Aldern; Jean-Marc Bovet; William R Freeman
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-11       Impact factor: 4.799

Review 3.  Comparative tolerability of therapies for cytomegalovirus retinitis.

Authors:  S Walmsley; A Tseng
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

Review 4.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

5.  Intraocular pressure in patients with human immunodeficiency virus, correlation with TCD4, viral load and demographic characteristics: a case-control study.

Authors:  Leonardo Medlig de Sousa Cravo; Ana Luiza Biancardi; Thamiles Batista Ronconi; Vinicius Layter Xavier; Haroldo Moraes
Journal:  Clin Ophthalmol       Date:  2019-08-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.